Latest market price
38.76
+0.17+0.44%
TA
Loading chart...
Snapshot
| Index | — | P/E | 12.58 | EPS (ttm) | 3.08 | Insider Own | — | Shs Outstand | 58.24M | Perf Week | 7.28% |
| Market Cap | 2.26B | Forward P/E | 8.72 | EPS next Y | 4.45 | Insider Trans | -0.18% | Shs Float | 50.20M | Perf Month | -2.05% |
| Enterprise Value | 1.74B | PEG | 1.72 | EPS next Q | 1.11 | Short Float | 10.78% | Perf Quarter | 8.88% | ||
| Income | 180.00M | P/S | 2.35 | EPS this Y | 22.21% | Short Ratio | 6.03 | Perf Half Y | 21.77% | ||
| Sales | 959.00M | P/B | 2.26 | EPS next Y | 13.57% | ROA | 13.20% | Short Interest | 5.41M | Perf YTD | 3.58% |
| Book/sh | 17.15 | P/C | 3.38 | EPS next 5Y | 7.32% | ROE | 20.06% | 52W High | 43.49 -10.88% | Perf Year | 32.20% |
| Cash/sh | 11.47 | P/FCF | 6.36 | EPS past 3/5Y | -3.01% — | ROIC | 14.96% | 52W Low | 25.90 49.65% | Perf 3Y | 99.69% |
| Dividend Est. | — | EV/EBITDA | 6.32 | Sales past 3/5Y | 25.61% 40.24% | Gross Margin | 75.42% | Volatility | 2.95% 4.00% | Perf 5Y | -5.07% |
| Dividend TTM | — | EV/Sales | 1.82 | EPS Y/Y TTM | -0.65% | Oper. Margin | 24.03% | ATR (14) | 1.51 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 3.45 | Sales Y/Y TTM | 24.22% | Profit Margin | 18.88% | RSI (14) | 51.06 | Recom | 2.54 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.48 | EPS Q/Q | 88.24% | SMA20 | 1.36% | Beta | 0.99 | Target Price | 48.67 |
| Payout | 0.00% | Debt/Eq | 0.15 | Sales Q/Q | 30.50% | SMA50 | -2.52% | Rel Volume | 0.91 | Prev Close | 38.59 |
| Employees | 293 | LT Debt/Eq | 0.13 | Earnings | Nov 04 | SMA200 | 11.73% | Avg Volume | 958.88K | Price | 38.76 |
| IPO Date | Aug 19, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 33.84% 4.19% | Net Debt/EBITDA | -1.86 | Volume | 871,271 | Change | 0.44% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-29-26 | Reiterated | Mizuho Securities | Outperform | $51 → $49 |
| Oct-01-26 | Reiterated | Deutsche Bank | Hold | $39 → $42 |
| Aug-26-26 | Initiated | Wolfe Research | Outperform | $60 |
| Aug-05-26 | Reiterated | Deutsche Bank | Hold | $36 → $39 |
| Aug-05-26 | Reiterated | UBS | Neutral | $33 → $37 |
| Aug-05-26 | Reiterated | Truist Securities | Hold | $45 → $34 |
| Aug-04-26 | Reiterated | Oppenheimer | Outperform | $62 → $70 |
| Jul-31-26 | Reiterated | Mizuho | Outperform | $50 → $51 |
| Jun-30-26 | Reiterated | Deutsche Bank | Hold | $31 → $36 |
| Feb-23-26 | Reiterated | Deutsche Bank | Buy | $31 |
Latest News· Times ET
Oct-28-26
Oct-28-2611:01AM
Oct-26-26
Oct-22-26
10:41AM
12:19AM
Oct-21-26
Oct-21-2602:46AM
Oct-20-26
Oct-20-2608:05AM
Oct-19-26
Oct-19-2608:07AM
Oct-16-26
Oct-13-26
Oct-13-2602:38AM
Oct-12-26
11:22AM
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next?defenseworld.net
10:46AM
10:14AM
Oct-08-26
Oct-08-2604:10PM
Company
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 959 | 868 | 715 | 582 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 237 | 198 | 157 | 121 | — | — | — | — | — | |
| Gross Profit | 724 | 670 | 558 | 461 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 272 | 272 | 221 | 193 | — | — | — | — | — | |
| Research and Development | 221 | 190 | 146 | 76 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 230 | 208 | 191 | 192 | — | — | — | — | — | |
| Interest Expense | 14 | 15 | 17 | 24 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 25 | 21 | 18 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | 241 | 215 | 192 | 173 | — | — | — | — | — | |
| Income Taxes | 60 | 56 | 46 | 45 | — | — | — | — | — | |
| Consolidated Net Income | 180 | 159 | 145 | 129 | — | — | — | — | — | |
| Net Income From Continuing Operations | 180 | 159 | 145 | 129 | — | — | — | — | — | |
| Net Income | 180 | 159 | 145 | 129 | — | — | — | — | — | |
| EPS (Recurring) | 3.13 | 2.76 | 2.56 | 2.17 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.13 | 2.76 | 2.56 | 2.17 | — | — | — | — | — | |
| EPS (Diluted) | 3.08 | 2.71 | 2.51 | 2.13 | — | — | — | — | — | |
| EBITDA | 276 | 255 | 233 | 222 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 12.58 | 13.81 | 13.71 | 15.16 | — | — | — | — | — | |
| Price To Sales Ratio | 2.34 | 2.46 | 2.74 | 3.27 | — | — | — | — | — | |
| Gross Margin | 75.50 | 77.19 | 78.04 | 79.21 | — | — | — | — | — | |
| Operating Margin | 23.98 | 23.96 | 26.71 | 32.99 | — | — | — | — | — | |
| Net Margin | 18.77 | 18.32 | 20.28 | 22.16 | — | — | — | — | — | |
| Shares Outstanding | 58 | 57 | 57 | 59 | — | — | — | — | — | |
| Market Capitalization | 2,248 | 2,133 | 1,961 | 1,906 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 18 '26 | Sale | 43.05 | 35,852 | 1,543,590 | 13,115 | Sep 18 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 18 '26 | Option Exercise | 30.39 | 35,852 | 1,089,610 | 48,967 | Sep 18 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 17 '26 | Option Exercise | 30.48 | 800 | 24,384 | 13,915 | Sep 18 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 17 '26 | Sale | 43.00 | 800 | 34,400 | 13,115 | Sep 18 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 16 '26 | Sale | 43.01 | 1,800 | 77,426 | 13,115 | Sep 18 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 16 '26 | Option Exercise | 30.48 | 1,800 | 54,864 | 14,915 | Sep 18 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 08 '26 | Sale | 42.96 | 28,454 | 1,222,259 | 13,115 | Sep 09 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 08 '26 | Option Exercise | 30.49 | 22,954 | 699,942 | 36,069 | Sep 09 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Sep 04 '26 | Sale | 41.98 | 5,500 | 230,911 | 18,615 | Sep 09 |
| Budur Kumar | CHIEF MEDICAL OFFICER | May 01 '26 | Option Exercise | 0.00 | 18,750 | 0 | 32,997 | May 18 |
| Zaeske Adam H. | CHIEF COMMERCIAL OFFICER | Apr 07 '26 | Option Exercise | 0.00 | 7,500 | 0 | 7,500 | Apr 09 |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | Jan 26 '26 | Sale | 37.15 | 3,746 | 139,171 | 24,521 | Jan 28 |
| Budur Kumar | CHIEF MEDICAL OFFICER | Jan 25 '26 | Option Exercise | 0.00 | 2,662 | 0 | 2,662 | Jan 26 |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | Jan 25 '26 | Option Exercise | 0.00 | 4,725 | 0 | 4,725 | Jan 26 |
| Serafin Andrew | CHIEF STRATEGY OFFICER | Jan 25 '26 | Option Exercise | 0.00 | 2,600 | 0 | 2,600 | Jan 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.